

**Delivery of Cinnamic Aldehyde Antioxidant Response Acti-vating nanoParticles
(ARAPas) for Vascular Applications**

Ana E. Cartaya ^{1,2,3,†}, Halle Lutz ^{3,†}, Sophie Maiocchi ^{1,2}, Morgan Nalesnik ⁴, and Edward S. M.
Bahnsen ^{1,2,3,4,5,*}

¹Department of Surgery, Division of Vascular Surgery, ²Center for Nanotechnology in Drug
Delivery, ³Department of Pharmacology, ⁴ Curriculum in Toxicology & Environmental Medicine,

⁵Department of Cell Biology & Physiology, and McAllister Heart Institute. University of North
Carolina at Chapel Hill, NC 27599

† AEC and HL contributed equally and share first authorship

*To whom correspondence should be addressed:

Edward Moreira Bahnsen, PhD.

Center for Nanotechnology in Drug Delivery

125 Mason Farm Rd, Office 2102. University of North Carolina at Chapel Hill

Chapel Hill, NC 27599

Tel 919-843-0842

Email: edward_bahnsen@med.unc.edu




Figure S1. MTT assay for VSMC treated with PL101, CA, or CA-ARAPAs. Vascular smooth muscle cell were treated with various concentrations of (A) Pluronic L101, (B) Cinnamic Aldehyde, and (C) CA-ARAPAs (at 0.01wt% of Pluronic L101). Dose-Response curve was fit using OriginPro and the EC50 calculated and presented in figure 3 of the main text.




Figure S2. Whole membranes for the Nrf2 WB. Vascular smooth muscle cells were treated (A) Pluronic L101 (0.05%), Cinnamic Aldehyde (100 μ M), or CA-ARAPas (Pluronic L101 0.05% - CA 100 μ M). To the left, the membranes were probed against Nrf2, to the right the same membranes show the corresponding loading controls probed against β -actin.